Watching us go through the "supposed" integration with a recently purchased company, it's clear that Paulson leaving didn't help. The US group is beholden to the global team and is ruled by fear. Decisions are rare and churn is eternal. Legacy Ipsen held in limbo for months, employees from Epizyme cut out of the mix. Oncology business unit is a mess - both commercial and medical. This isn't the Ipsen anyone who knows what the original Ipsen was, and it's a shame on so many levels.